Galectin-9, a β-galactoside-binding protein, is defined as a negative regulator of T helper 1 (Th1) immune responses, favoring Th2 bias. Systemic immunity in patients with metastatic melanoma is predominantly Th2 biased. We hypothesized that galectin-9 can modulate systemic immunity toward Th2 polarization in patients with advanced melanoma. The presence or concentration of galectin-9 was assessed in tumors and plasma, in patients with metastatic melanoma. The immunomodulatory function of galectin-9 was determined by exposing human peripheral blood mononuclear cells to galectin-9 in vitro. Galectin-9 was expressed in 57% of tumors and was significantly (3.6-fold) increased in the plasma of patients with advanced melanoma compared with healthy controls (P < 0.001). High plasma galectin-9 concentration was associated with systemic Th2 polarization and reduced 2-year survival compared with low/no galectin-9 expression. In-vitro, galectin-9 reduced proliferation of healthy peripheral blood mononuclear cells, and promoted Th1 cell apoptosis, Th2-biased cell phenotypes, and cytokine secretion. Galectin-9 also stimulated monocyte differentiation toward an M2 macrophage phenotype, as assessed by chemokine/ cytokine secretion and CD206 expression, observed both in vitro as well as in patients with metastatic melanoma. Elevated galectin-9 in patient plasma correlated with Th2 systemic bias and less favorable clinical outcomes for patients with metastatic melanoma. This Th2 bias appears to be not only a feature of the known mechanisms of Th1 apoptosis by T-cell immunoglobulin and mucin-domain containing-3 binding, but also mediated by myeloid cell differentiation toward an M2 phenotype, that favors tumor progression. These data support galectin-9 as a novel therapeutic target for patients with metastatic melanoma. Melanoma Res 26:429-441
Introduction
Understanding immune regulation in the context of the tumor microenvironment is necessary and critical for effective advancements in cancer therapy. Immunotherapies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-program death 1 (PD-1), have revolutionized cancer therapeutics by blocking the ability of the tumor to impede T-cell activation, resulting in prolonged survival in metastatic melanoma [1, 2] . Nonetheless, for these checkpoint inhibitors to significantly impact patient outcomes, these therapies require a functional endogenous immune system. However, patients with cancer show systemic immune responses consistent with chronic inflammation (Th2-biased helper T-cells), which creates an optimal environment for tumor development [3, 4] . The loss of Th1 type responses and the promotion of Th2 type immunity has shown to negatively affect clinical responses to therapy and patient outcomes [5, 6] . Recognizing this problem, monoclonal antibodies against chronic inflammatory-promoting proteins have been developed and shown to have clinical efficacy. For example, blocking vascular endothelial growth factor limits its ability to promote angiogenesis and lymphangiogenesis-induced inflammation, which improves survival [7, 8] . Thus, investigation of other protumor targets that could be blocked to reactivate the immune system could lead to novel therapies.
One such protein that has been characterized as an inhibitor of Th1 immune responses is galectin-9. Galectins are carbohydrate-binding proteins that are evolutionarily conserved and play pleiotropic roles in immunity [9] . First defined as an eosinophil chemoattractant, galectin-9 has been implicated in the regulation of Th2 type responses in allergy models [10, 11] . Others have shown that in transgenic Th1 biased mice, there is an increase in myeloid-derived suppressor cells after the addition of galectin-9 [12] . T-cell immunoglobulin and mucin-domain containing-3 (Tim3) is the most well-characterized binding partner of galectin-9, and their interaction was shown to negatively regulate Th1 type responses through apoptosis of activated CD4 + cells All supplementary digital content is available directly from the corresponding author. [13, 14] . Remarkably, galectin-9/Tim3 regulation at the feto-maternal interface seems to be critical for the development and maintenance of healthy pregnancies [15, 16] . Many similarities exist between tumor and trophoblastic development and regulation in promoting immune tolerance [17, 18] . As Th1 responses are correlated with a less favorable immune environment for tumor growth and fetal development, galectin-9 may be an important target that modulates immunity in support of the tumor. The Tim3/ galectin-9 interaction shares the same outcome, specifically apoptosis and cell exhaustion, as the PD-1 and PD-ligand (PD-L1) signaling pathway, which has been characterized extensively and been shown to be a clinically effective target in many tumor types [19, 20] . However, galectin-9 and its function in human metastatic melanoma remain largely unknown. The present study was designed to define the relevance and role of galectin-9 on immunity in human metastatic melanoma. Our results indicate that galectin-9 could be a prognostic marker in metastatic melanoma. These findings support the rationale for preclinical development of galectin-9 targeted immunotherapies.
Materials and methods

Patient selection
A total of 276 patients with metastatic melanoma and 40 healthy controls were examined in our study. Baseline blood specimens, before treatment, were collected from patients on three clinical trials: N057e, N0775, and N0879. All available specimens were run from each study. Phase II clinical trial N057e was conducted by the North Central Cancer Treatment Group [21] . We obtained plasma from 51 patients enrolled in N057e for our studies. For the randomized phase II trial N0775, we obtained samples from 82 patients in this study [22] . N0879 was a randomized Phase II and plasma was utilized from 143 patients. Informed consent was obtained from all patients to participate in N057e, N0775, and N0879, and studies were approved by the Mayo Clinic Institutional Review Board.
Protein determination by ELISA and multiplex
Plasma samples were isolated from the blood of metastatic melanoma patients and healthy donors, and then frozen until analysis. Concentrations of galectin-9, interferon (IFN)-γ, inducible protein (IP)-10, interleukin (IL)-10, and monocyte chemoattractant protein (MCP)-1 were determined by an enzyme-linked immunosorbant assay (ELISA) using the human DuoSet antibodies (R and D Systems, Minneapolis, Minnesota, USA) according to the manufacturers' instructions. Protein concentration was determined using a seven-point standard curve at 450 nm using a VersaMax microplate reader (Molecular Devices, Sunnyvale, California, USA).
Supernatants from healthy peripheral blood mononuclear cells (PBMCs), cultured with and without 2 µg/ml galectin-9, were collected for multiplex analysis. Lymphocytes were isolated from those same PBMC samples through CD14 positive selection and monocytes were isolated through negative selection of CD14 + cells (Miltenyi Biotec Inc., San Diego, California, USA). Proteins were measured using the MagPlex Milliplex human 38 cytokine panel (Millipore, Billerica, Massachusetts, USA) according to the manufacturer's instructions. This kit includes EGF, FGF-2, Eotaxin, TGF-α, G-CSF, Flt-3L, GM-CSF, Fractalkine ,  IFNα2, IFN-γ, GRO, IL-10, MCP-3, IL-12p40, MCD, IL-12p70, IL-13, IL-15, sCD40L, IL-17A, IL-1RA, IL-1α, IL-9,  IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6 , IL-7, IL-8, IP-10, MCP-1, macrophage inflammatory protein 1 (MIP-1)α, MIP-1β, tumor necrosis factor (TNF)-α, TNFβ, and vascular endothelial growth factor. Samples were run using Luminex xPONENT technology (Luminex Corporation, Austin, Texas, USA) and concentrations were determined using a standard curve from 1.6 to 5000 pg/ml, with Milliplex Analyst software (VigeneTech, Carlisle, Massachusetts, USA). All samples were run in duplicate and averaged to determine their concentration.
Tissue histology
Tumor samples were retrieved from 118 patients with resected metastatic melanoma lesions as a part of routine clinical care from 1993 to 2004 as reported previously [23] . Primary antibodies for galectin-9 and PD-L1 (BD Biosciences, San Jose, California, USA) were diluted according to the manufacturer's instructions. Tumor microarray slide images were digitized using the Olympus BLISS HD Virtual Microscopy System (Olympus America Inc., Center Valley, Pennsylvania, USA).
Ten metastatic melanoma tumors were fixed in formalin and embedded in paraffin. Antibodies against galectin-9 (AbCam, Cambridge, Massachusetts, USA), PD-L1, CD68, and S100 (Novus Biologics, Littleton, Colorado, USA) were utilized for staining, along with isotype controls by Histoserv Inc. (Germantown, Massachusetts, USA). Stains were digitized and imported into ImmunoHistoChemistry (IHC) score (Bacus Laboratories, Lombard, Illinois, USA). Representative images are shown at × 20.
Proliferation assay
PBMCs were isolated from the blood of healthy donors for measurement of proliferative capacity in the presence of recombinant human galectin-9 (R and D Systems). In three separate experiments, cells from two allogeneic healthy controls were mixed together: one of the PBMC samples was irradiated (stimulator). Culture conditions included 20 U/ml IL-2 in RPMI + 10% fetal bovine serum and experimental wells included 2 µg/ml galectin-9. In a 96-well plate, 100 000 responder cells in 100 µl were added with 100 µl of serial diluted irradiated cells in triplicate. Cultures were incubated for 3 days at 37°C and 5% CO 2 before the addition of 1 µC/well of H 3 thymidine overnight. The plate was washed and transferred to a 96-well filter plate. Scintillation fluid was added and counts per minute were recorded on a scintillation counter. Averages and SD were calculated from each replicate and combined between all three experiments.
Cellular apoptosis assay
PBMCs were plated at 100 000/well in a 96-well plate with 2 µg/ml galectin-9, 10 µg/ml anti-Tim3 neutralizing antibody (Clone 344801; R and D Systems), or both and incubated for 24 h at 37°C and 5% CO 2 . Blocking was determined by phospho-flow cytometry utilizing phospho-Y265 PE (Millipore) and Tim3 APC or secondary staining (R and D Systems). Cultures were assayed for apoptosis using the APO-DIRECT flow cytometry apoptosis method (Millipore) according to the manufacturers' instructions. In brief, extracellular staining was carried out for 30 min with CD4-PE, CD8-PE-Cy5, and CD14-PE-Cy7 (BD Biosciences). Cells were fixed and incubated overnight at − 20°C in 70% ethanol. Cells were washed and stained for DNA breaks by FITCtagged nucleotides, resuspended in FACS buffer, and read on a Guava easyCyte flow cytometer (Millipore). A total of 20 000 events were counted and apoptotic, dead, and live cells were compared between groups with and without galectin-9.
Flow cytometry
Mononuclear cells from healthy donors (n = 15) were isolated from buffy coats and incubated overnight at 37°C and 5% CO 2 with or without 2 µg/ml of galectin-9. Cells were washed and four-color flow cytometry was run to determine the effects of galectin-9 on Tim3 + and Tim3 − CD4 and CD8 cells. Permeabilization was carried out in 0.5% saponin. Antibodies were acquired from BD Bioscience and Th cells (CD3 + CD4 + ), cytotoxic T-cells (CD3 + CD8 + ), and T regulatory (T-regs) cells (CD4 + CD25 + FOXP3 + ), along with CD294, PD-1, and Tim3, were probed. Experiments were run on a Guava easyCyte 8HT flow cytometer (Millipore), with 20 000 events counted.
Macrophage culture
THP-1 (TIB-202) cells, a human monocytic cell line, were obtained within the last 2 months from ATCC (Manassas, Virginia, USA), where it was authenticated using single tandem repeat profiling. Healthy CD14 + monocytes were isolated out of fresh blood from healthy donors using a Ficoll-Paque gradient (GE HealthCare, Pittsburgh, Pennsylvania, USA) and the MACS Human Monocyte Isolation Kit (Miltenyi Biotech Inc.). THP-1 were differentiated into macrophages with 150 nmol/l phorbol myristate acetate (PMA) for 24 h and then polarized to M2 phenotype for 72 h with IL-4 and IL-13 using a previously published method [24] or 2 µg/ml of galectin-9. CD14 + cells were differentiated into macrophages with 150 nmol/l PMA for 24 h, and then polarized to an M2 phenotype for 48 h with IL-4 and IL-13, or 2 µg/ml galectin-9 as above. To determine M2 status, cells were stained for CD206-PE, CD68-FITC, and CD14-PC7 (BD Biosciences) by flow cytometry. Supernatants were tested by ELISA for IFN-γ and IP-10 (M1) and IL-10 and MCP-1 (M2) secretion as above.
Data analysis
Experimental samples were averaged and statistical comparisons were determined using a two-tailed Student's t-test. High versus low galectin-9 threshold was determined by recursive partitioning and compared using χ 2 -tests [25] . The probability of 2-year survival on the basis of galectin-9 was estimated by Kaplan-Meier curves and compared by log-rank tests. Survival was defined as the date of initial blood draw to the date of death or the last follow-up. Univariate analysis of patient characteristics between low/high galectin-9 cohorts was compared using a χ 2 -test. Multivariate analysis was carried out using the Cox proportional hazard regression model. JMP 10.0.0 (SAS Institute Inc., Cary, North Carolina, USA) was used for statistical analysis. All tests were two sided and a P-value less than 0.05 was considered statistically significant. For multiplex data, significance was defined by a P-value of less than 0.001 after utilizing the Holm-Sidak method to correct for multiple comparisons.
Results
Patient characteristics
Two-hundred and seventy six patients were included in this study. Date of death was missing for only three patients. The majority of patients were men, stage M1c, and between 50 and 60 years old. Supplementary Table S1 shows the clinic-pathologic differences between the high soluble galectin-9 (≥1532 pg/ml) and low soluble galectin-9 (< 1532 pg/ml) patient groups determined by recursive partitioning. There were no significant differences between the two groups based on sex, age, LDH, or clinical stage.
Galectin-9 is elevated in metastatic melanoma
By ELISA, plasma samples from patients with metastatic melanoma were compared with healthy controls for the concentration of soluble galectin-9. Galectin-9 concentrations from healthy persons (n = 16) had a mean of 1192 pg/ml (SEM 125.5), whereas patients with metastatic melanoma plasmas (n = 20) had an average 3.6-fold higher concentration: 4283.78 pg/ml (SEM 350.3; P < 0.0001) ( Fig. 1a ). Next, tumor microarrays of metastatic melanoma tumors were analyzed for the expression of galectin-9 and PD-L1. Of the 118 tumors, 51% coexpressed galectin-9 and PD-L1, 34% were PD-L1 positive, 6% were galectin-9 positive, and 9% were negative for both receptors (Fig. 1b ). To determine where staining for galectin-9 showed the highest positivity, 10 stage IV tumor biopsy tissues were stained for S100, PD-L1, and galectin-9. Figure 1c shows a representative stain for these biomarkers, indicating the highest staining patterns for galectin-9 at the interface between the tumor and the noncancerous stroma (S100 negative), which is comparable to known PD-L1 staining [19] . Using the IHC score to determine the percentage of the tumor core, tumor edge, and noncancerous tissue that are positive for each marker, it was observed that although the tumors differed in their staining pattern, the highest staining intensity for galectin-9 was on the edge (P = 0.0003) and in the tumor core (P = 0.02) compared with S100-negative stromal tissue ( Fig. 1d ). PD-L1 staining was significantly increased on the tumor edge (P = 0.02), but not the core compared with noncancerous tissue.
High galectin-9 correlates with worse 2-year survival Two-hundred and seventy six plasma samples from patients with metastatic melanoma at baseline, before participation in three different clinical trials, were measured for galectin-9 concentration by ELISA. Concentrations were then divided into high (≥1532 pg/ml) or low (< 1532 pg/ml) galectin-9 using recursive partitioning, as in glioblastoma [25] . Two years after blood was drawn, patients with high levels of galectin-9 correlated with poor survival ( Fig. 2a) , with a median of 340 days [95% confidence interval (CI) 370-621 days] compared with those with low galectin-9 in plasma (510 days; 95% CI 293-391 days; P = 0.02). In a multivariate model, high galectin-9 remained significantly associated with poor survival after adjustment for age, sex, and LDH ( Supplementary Table S2 ). As expected, LDH also remained predictive for worse survival in our model (risk ratio 1.8, 95% CI 1.3-2.4; P = 0.0002).
To determine the systemic immunological impact of high versus low galectin-9 with known immune phenotypes, we determined the Th1 : Th2 ratio in PBMCs defined as Tumor core Edge Noncancerous IHC area (%)
Relevance of galectin-9 in metastatic melanoma. (a) Concentration of galectin-9 in the plasma of healthy donors (n = 16) and stage IV melanoma patients (n = 24). (b) Percentage of stage IV melanoma tumors (n = 118) expressing PD-L1 and/or galectin-9. (c) Metastatic melanoma tumors stained for galectin-9 or PD-L1. (d) Total percentage of the area on a tumor core, edge, or healthy tissue that expresses galectin-9 or PD-L1 (×20 magnification). *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001. IHC, immunohistochemistry; PD-L1, program death ligand 1.
cellular CD4 + Tim3 + (Th1) : CD4 + CD294 + (Th2), the concentration of Th1 biasing cytokine IFN-γ, and the concentration of Th2 biasing cytokines IL-4 and IL-10 in plasma from this same patient population by flow cytometry and multiplex analysis. The Th1 : Th2 ratio was significantly lower, thus more Th2 polarized, in the high galectin-9 group compared with the low galectin-9 group (0.96 vs. 1.39, P = 0.01) ( Fig. 2b ). IFN-γ was lower in patients in the high galectin-9 group (18.2 vs. 5.3 pg/ml, P = 0.02) ( Fig. 2c ). Th2 biasing cytokines IL-4 and IL-10 were significantly increased in the plasma of patients who had high galectin-9 levels (1.9 vs. 0.7 pg/ml, P = 0.03; 7.8 vs. 1.5 pg/ml, P = 0.03, respectively) ( Fig. 2d and e ). Interestingly, the percentage of CD4 + Tim3 + cells did not differ (P = 0.35) between the high versus the low galectin-9 cohort (data not shown).
Galectin-9 modulates immunity
Using irradiated allogeneic blood cells, healthy PBMCs were stimulated to induce cellular expansion to foreign antigen in the presence and absence of galectin-9. Irradiated cells were serially diluted from 100 000 cells down to 50 cells per 100 000 viable PBMCs. In the presence of 2 µg/ml galectin-9, proliferation was damped up to a dilution of 1 : 8 responders to stimulators ( Fig. 3a) . Then, the allogeneic stimulus was strong enough to override galectin-9 effects and initiate proliferation similar to the control.
To assess the role of galectin-9 and the Tim3 receptor on apoptosis, TUNEL staining was used to measure the viability of Th (CD4), T cytotoxic (CD8), and monocytic (CD14) cell populations. The effectiveness of Tim3 blocking was determined by phospho-flow cytometry by measuring the Tim3 + p-Y265 + signal ( Supplementary  Fig. S1 ). After 24 h with galectin-9, there was a significant increase in the percentage of cellular apoptosis in CD4 + , CD8 + , and CD14 + cells compared with untreated controls (36 vs. 20.5%, P = 0.001; 37.8 vs. 9.7%, P = 0.0007; 45.6 vs. 20%, P = 0.03, respectively) ( Fig. 3b ). With the addition of a Tim3 blocking antibody, there was no difference in the percentage of apoptosis initiated by galectin-9 in the CD8 + and CD14 + populations. However, there was a significant difference in apoptosis between CD4 + cells treated with galectin-9 and the anti-Tim3 antibody compared with those treated with galectin-9 alone (21.76 vs. 36%, P = 0.003). These data suggest that CD4 apoptosis is dependent on Tim3 binding, whereas galectin-9 initiates CD8 and CD14 apoptosis independent of Tim3.
Next, we sought to understand how galectin-9 affects the phenotype of cells that are positive for Tim3 compared with those that do not express Tim3 by flow cytometry (Fig. 3c) . After a 48 h incubation with galectin-9, PD-1 and Tim3 receptors were measured on CD4 + cells and the result was a decrease in the CD4 + Tim3 + population (413 vs. 139, P = 0.02), the double-positive population did not change (120 vs. 91, P = 0.47), and the Tim3 − PD-1 + population increased in the presence of galectin-9 (487 vs. 861, P = 0.0008). CD294, a receptor indicative of a Th2 biased cell, showed a significant increase in the number of CD4 + Tim3 − cells after galectin-9 incubation compared with untreated cells (1270 vs. 733, P = 0.002), but did not affect the doublepositive population (120 vs. 122, P = 0.97). In the cyto- Finally, cytokines secreted by PBMCs and CD14-depleted lymphocytes after a 12 h exposure to galectin-9 were evaluated to determine the immune milieu induced by galectin-9. PBMC cultures secreted high amounts TNF-α (P = 0.003) and IL-1β (P < 0.0001) in the presence of galectin-9 ( Fig. 3d ). Th2 biasing cytokines IL-4 (P = 0.001), IL-6 (P = 0.003), and IL-10 (P = 0.02) also increased significantly after galectin-9 incubation. Strikingly, when the CD14 + monocytes were removed, the overall cytokine secretion decreased 30-fold, although IL-10 (P < 0.0010) and IL-6 (P = 0.005) remained elevated (Fig. 3e ). Results from other chemokines and cytokines were nonsignificant or beyond the limit of detection ( Supplementary Tables S3  and S4 ). These effects suggest that galectin-9 induces a chronic inflammatory state that is driven predominantly by the myeloid population.
Galectin-9 promotes the M2 phenotype Similar to galectin-9, CD68 + macrophages also stain strongest around the edge of the tumor and were most abundant at the tumor/stromal interface (P = 0.005) compared with noncancerous tissue (S100 negative) and tumor core ( Fig. 4a) . To determine the role of macrophages, which are abundant in the tumor microenvironment, we assessed changes in chemokine and cytokine secretion with the addition of galectin-9 for 12 hours to healthy human CD14 + monocytes. Results show that M2 biasing chemokines MCP-1 (4567 vs. 615 pg/ml; P < 0.0001) and MIP-1α (2138 vs. 12 pg/ml; P < 0.0001) were increased after galectin-9 incubation; however, M1 promoting IP-10 (97 vs. 75 pg/ml; P = 0.64) was not significantly changed ( Fig. 4b) . Cytokines were measured for M1 or M2
Galectin-9 in metastatic melanoma Enninga et al. 433 phenotype after the addition of galectin-9. M2 cytokines IL-10 (1594 vs. 11.6 pg/ml; P = 0.002), IL-4 (7.3 vs. 4.9 pg/ ml; P < 0.0001), and IL-6 (3914 vs. 5.3 pg/ml; P < 0.0001) were also increased in the presence of galectin-9, whereas M1 cytokine IFN-γ (4.7 vs. 2.7; P = 0.27) was not affected by treatment (Fig. 4c) . Interestingly, TNF-α (4427 vs.
6.84 pg/ml; P < 0.0001) and IL-1β (2122 vs. 3.5 pg/ml, P = 0.0004) increased with galectin-9. This suggests that the M2 phenotype could possibly be further defined as M2b, which secrete IL-10, TNF-α, IL-1β, and IL-6 [26] . Other chemokines and cytokines measured were nonsignificant or beyond the limit of detection of the assay ( Supplementary Table S5 ). Together, our data suggest that galectin-9 biases monocytes toward an M2, or possibly M2b, immunosuppressive phenotype.
To more clearly define the effect that galectin-9 has on promoting an M2 phenotype, we utilized the THP-1 human monocyte cell line to study CD206 expression and cytokine/chemokine secretion in vitro. Macrophage differentiation and polarization to M2, defined by CD206 expression, was completed using published methods [24] . After 72 h, surface expression of CD206 was increased on the CD68 + macrophage population treated with galectin-9 (MFI = 102; P = 0.037), similar to IL-4/IL-13 (MFI = 101; P = 0.047) compared with the control (MFI = 68) ( Fig. 5a ). Supernatants from THP-1 cultured cells were measured for M1 (IP-10 and IFN-γ) and M2 (MCP-1 and IL-10) markers after 72 h with galectin-9, IL-4/IL-13, or PMA by ELISA. M1 markers IP-10 and IFN-γ were low for all treatments, whereas M2 chemokine MCP-1 was significantly increased in both IL-4/IL-13 and galectin-9 culture compared with the control (163 vs. 9 pg/ml, P = 0.0004; 165 vs. 9 pg/ml, P < 0.0001, respectively) ( Fig. 5a ). IL-10 was also elevated in the supernatants of macrophages treated with both IL-4/IL-13 or galectin-9 compared with controls (65 vs. 18 pg/ml, P < 0.0001; 58 vs. 18 pg/ml, P = 0.001, respectively). To determine whether this effect can be reproduced in primary monocytes, we incubated CD14 + cells for 48 h in IL-4/IL-13 or galectin-9 and measured CD206 expression. Although more heterogeneous, galectin-9 incubation with healthy CD14 + monocytes resulted in an increase in CD206 expression with galectin-9 incubation (MFI = 104; P = 0.005) similar to IL-4/IL-13 (MFI = 116, P = 0.001) compared with the Galectin-9 modulates immunity promoting a suppressive immune environment in vitro. (a) Average and SD of three independent autologous mixed lymphocyte reactions using PBMCs isolated from healthy donors with or without exogenous galectin-9 (2 µg/ml). (b) Percentage of CD4 + , CD8 + , and CD14 + cells undergoing apoptosis after a 24 h incubation with 2 µg/ml galectin-9 and a 10 µg/ml Tim3 neutralizing antibody (n = 9). (c) Changes in the T-cell phenotype after a 48 h incubation with 2 µg/ml galectin-9 (n = 15) *P ≤ 0.05. (d) Cytokine secretion of all PBMCs after a 12 h incubation with 2 µg/ml galectin-9 (three independent experiments; n = 5). (e) Cytokine secretion of CD14 depleted lymphocytes incubated with 2 µg/ml galectin-9 (three independent experiments; n = 5) *P ≤ 0.001. IL-4, interleukin-4; PBMCs, peripheral blood mononuclear cells; PD-1, program death-1; TNF-α, tumor necrosis factor-α; Tim3, T-cell immunoglobulin and mucin-domain containing-3.
Galectin-9 in metastatic melanoma Enninga et al. 435 PMA-only control (MFI = 79) ( Fig. 5b) . Primary CD14 differentiated macrophages secreted higher levels of M2 cytokine IL-10 (122.4 vs. 36.6 pg/ml, P = 0.007) and M2 chemokine MCP-1 (747.2 vs. 136.2 pg/ml, P = 0.035) compared with the control and relative to M2 biasing conditions (137.7 and 672.2 pg/ml, respectively) ( Fig. 5b) . No difference was observed between IFN-γ (9.67 vs. 11.6 pg/ml, P = 0.17; 9.63 vs. 11.6 pg/ml, P = 0.18, respectively) and IP-10 (14.6 vs. 14.2 pg/ml, P = 0.98; 12.1 vs. 14.2 pg/ml, P = 0.84, respectively) after the addition of galectin-9 or IL-4/IL-13 compared with the control. The results indicate that galectin-9 acts on both THP-1 culture cells and primary monocytes to promote an M2 phenotype. Considering that galectin-9 upregulated CD206 on macrophages in vitro, we analyzed CD206 expression on circulating CD14 + PBMCs from 276 pretreatment metastatic melanoma patients and 270 healthy, age-matched controls. An increase in the frequency of CD14 + CD206 + monocytes was observed in the melanoma population compared with the healthy controls (8.94 vs. 6.47; P < 0.0001), indicating that high levels of galectin-9 may be acting on the myeloid population to promote the immunosuppressive phenotype observed in cancer patients (Fig. 5c ).
Discussion
Recent advancements in cancer immunotherapy have improved survival of patients with metastatic melanoma, nevertheless, the majority of patients will succumb to their disease. New therapies that rationally target other aspects of the host immunologic response to melanoma remain necessary, especially for patients who do not respond to existing immunotherapies. This study characterizes soluble galectin-9 and survival in metastatic melanoma, as well as defines immunoregulatory mechanisms of galectin-9 on human lymphoid and myeloid cells (Fig. 6 ). Our data suggest that galectin-9 (a) is highly expressed at the melanoma tumor edge, (b) is found in high concentrations in the plasma of metastatic melanoma patients, where it is associated with worse survival, independent of clinical factors such as LDH, (c) suppresses the Th1 phenotype through Tim3-dependent and independent apoptosis, (d) promotes T-cell tolerance independent of Tim3, and (e) enhances M2 macrophage polarization in vitro. Our results suggest that neutralizing galectin-9 functions may be an effective way to recover a Th1, tumor targeting immune state.
The immune system is highly redundant; thus, it is not surprising that the galectin-9/Tim3 interaction shares many of the same characteristics and functionalities of the PD-1/PD-L1 interaction, although the pathways by which they signal are different [27] . Tumors express the highest levels of galectin-9 at their edge, similar to PD-L1 staining [19] . This is advantageous for the tumor as it can interact more effectively to block activated tumor-specific T-cells and evade immune cell killing. We observed high levels of circulating galectin-9 in the blood of melanoma patients compared with the healthy controls. Similarly, soluble PD-L1 has been observed in patients with renal cell cancer and it has been shown to cause apoptosis of T-cells [28] . Previously, melanoma tumors expressing galectin-9 were found to correlate with improved patient survival [29] . However, these data did not include any measure of soluble galectin-9. Our analysis shows that those patients who have high levels of circulating galectin-9 have a worse 2-year survival than those with low levels of galectin-9. Galectin-9 may be both a biomarker and have therapeutic potential in metastatic melanoma.
We have also shown the importance of the Tim3-binding partner, galectin-9, in regulating immunity by Tim3-independent and Tim3-dependent mechanisms. Just as galectin-9 was first shown to interact with Tim3, the data also showed that removing Tim3 did not completely abolish the ability of galectin-9 to induce apoptosis of CD4 + T-cells [13] . Cells from Tim3 knockout mice treated with galectin-9 underwent apoptosis and secreted IFN-γ at the same rates as wild-type cells [30] . We observed that CD4 + apoptosis was dependent on Tim3, but not for CD8 + and CD14 + cells, which underwent apoptosis irrespective of this interaction.
These studies suggest an alternative binding partner for galectin-9 that has not yet been discovered. CD44 has been shown to interact with galectin-9 in an allergic inflammation model [11] , and more recently, this relationship has been described as a major promotor of T-regs through Smad3 [31] . Both studies were carried out in murine models; thus, future experiments to confirm and expand upon these results using human samples are warranted.
Galectin-9 promotes the secretion of Th2 cytokines IL-4, IL-6, and IL-10; however, it also consistently caused an increase in TNF-α and IL-1β. Although defined as proinflammatory, the role of TNF-α in suppressing and/ or promoting cancer remains controversial. Recently, Ras was defined as a critical regulator in diverting TNF-α function in each direction [32] . IL-1β, which is produced by myeloid cells, has also been shown to promote tumor growth and angiogenesis in a lung carcinoma model [33] . Human astrocytes stimulated with IL-1β caused an increase in galectin-9 expression [34] . Combined with our data, feedback regulation between galectin-9 and IL-1β is plausible. Interestingly, macrophages from an arthritis mouse model studied after treatment with galectin-9 showed decreased TNF-α and IL-1β, and increased IL-10 compared with controls [35] . As this arthritis model is considered Th1 biased, these contrary results parallel Tumor PD-1 Th2
CD294 T-reg
Proposed mechanism of galectin-9 immune modulation. Galectin-9 eliminates Th1 responses through apoptosis of Tim3 + T helper 1 cells while promoting immune tolerance through the increase of PD-1, CD294, and T regulatory cells (T-regs). Galectin-9 also modulates macrophages by stimulating an M2, protumor phenotype with the upregulation of CD206 and secretion of M2 chemokines and cytokines. IFN-γ, interferon-γ; IL-4, interleukin-4; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; PD-1, program death-1; Th1, T helper 1 cells; Tim3, T-cell immunoglobulin and mucin-domain containing-3; TNF-α, tumor necrosis factor-α. our cytokine findings in cancer, a Th2-biased disease. Thus, TNF-α and IL-1β, in the context of our study, may be promoting tumor growth through galectin-9-dependent mechanisms.
Tumor-associated macrophages can make up 5-40% of the solid tumor mass and have been defined as having a M2, tumor-promoting phenotype. The M2 phenotype has further been defined on the basis of the initial activation signal and chemokines/cytokines secreted [36] . Nevertheless, macrophage function and mechanism in malignancy remains incompletely understood because of the difficulty in translating animal results into humans and myeloid plasticity in fluid microenvironments inside the body [37] . High numbers of macrophages in tumors are typically associated with a poor prognosis [38] . In addition, M2 polarized macrophages have been shown to be indicative of poor survival in lung and cervical cancer [39, 40] . In the context of galectin-9, THP-1 monocytes modified to overexpress intracellular galectin-9 were shown to promote inflammatory cytokine production through NF-IL-6 and AP-1 [41] . We found that extracellular galectin-9 induced a marked increase in cytokine production by PBMCs, specifically TNF-α, IL-10, IL-4, IL-1β, and IL-6. The result was lost after removal of the CD14 population, suggesting an important interaction between myeloid cells and galectin-9. Cytokines secreted by the CD14 + population had a similar milieu as all PBMCs, and these cytokines have been defined in the context of the M2 phenotype [42] . Using gene expression analysis and western blots, TNF-α and IL-1β, which are typically considered M1, were found to be upregulated after lipopolysaccharide and immune complex addition and are characterized to be secreted by M2b regulatory macrophages [26, 43] . This phenotype is similar to an M1, but IL-4, instead of IFN-γ, is the predominant secreted cytokine. Galectin-9 induced secretion of TNF-α and IL-1β, along with M2 cytokines, suggesting that it could be another activator of an M2b regulatory phenotype. Further research into these specific M2 populations and galectin-9 is warranted, along with further development of myeloid markers to define each subset in vitro more clearly.
Incubation of THP-1 cells, a human monocyte cell line derived from acute monocytic leukemia, with IL-4 and IL-13 has been shown to induce an M2 phenotype in vitro [24] . Using this condition as a positive control, galectin-9 promoted the same M2 phenotype in THP-1 cells with increased expression of CD206 and secretion of MCP-1 and IL-10. CD206 is a C-type mannose receptor that binds and internalizes collagen and glycoproteins [42] . This bias toward an M2 phenotype was also observed in healthy human CD14 + monocytes cultured in the presence of galectin-9. The result was even higher levels of IL-10 and MCP-1 secretion compared with THP-1 cells in the presence of galectin-9. This added further confirmation as to the role of galectin-9 in modu-lating immunity toward a state that is favorable for the tumor.
The data indicate that galectin-9 may be a targetable molecule with clinical relevance for patients with metastatic melanoma. The ability of galectin-9 to regulate the immune system seems to be only partially dependent on Tim3 binding. Anti-Tim3 monoclonal antibodies have yielded positive preclinical results in tumor models. For example, tumor-bearing mice treated with anti-Tim3 antibodies had more IFN-γ-producing T-cells as well as increased tumor-infiltrating cells, which correlated with tumor reduction [44] . Administration of an anti-Tim3 antibody also led to an increase in Th1 cells and cytokines in a murine model [45] . Phagocytes were also inhibited by immunization with anti-Tim3 monoclonal antibodies in a C57BL/6 model [46] . These studies indicate the importance of Tim3 to peripheral tolerance; however, translation into humans has yet to be reported. Researchers have been obtaining promising results using Tim3 in combination with other inhibitory molecules. Fourcade et al. [47] utilized a blockade of PD-1 and Tim3 in a cancer vaccine for melanoma patients and observed an increase in CD8 + T-cells and antitumor cytokine production. In a preclinical melanoma model, inhibition of both Tim3 and Tim4 resulted in an increase in antitumor immune responses [48] . Unfortunately, these studies do not include any measure of galectin-9. Consistently, our data showed that the addition of galectin-9 to human T-cells induced the upregulation of PD-1 on the cell surface that was Tim3 negative. T-regs and CD4 + T-cells expressing CD294, a marker of Th2 polarization, also increased in the same manner. This result suggests that galectin-9 drives tumor-specific immune cell tolerance in a Tim3-independent manner. Thus, more research needs to be completed to understand the galectin-9, Tim3-independent mechanisms of immune tolerance.
Conclusion
To conclude, this work suggests that galectin-9 could be a targetable molecule as well as a possible biomarker of disease prognosis in melanoma. Although galectin-9 has been studied in the context of Tim3 in many animal models, translation into human disease has only just begun. We and others have found that galectin-9 generates many different consequences on the basis of the immune cell being studied [49] . It was observed that galectin-9 promotes apoptosis dependent and independent of Tim3 on the basis of cell type, as well as drives M2 differentiation of monocytes. There is a clear Tim3-independent effect that has not yet been defined because of challenges determining additional receptors, developing effective antibodies, as well as the fact that galectins can bind multiple surface proteins that elicit similar downstream effects [30, 50] . We noted that cells that were Tim3 negative upregulated tolerance receptors Galectin-9 in metastatic melanoma Enninga et al. 439 and promoted Th2 chemokine/cytokine secretion. Continued research into galectin-9 interactions and mechanisms to modulate immunity, promoting tumor growth, is justified. Together, these data indicate that therapeutic targeting of galectin-9 on tumors and in plasma is a logical next step in the development of immunotherapeutics in metastatic melanoma.
